Research Topics
Species | N O'DonovanSummaryAffiliation: Dublin City University Country: Ireland Publications
| Collaborators
|
Detail Information
Publications
Prospects for non-immunological molecular therapeutics in melanomaA J Eustace
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland
J BUON 15:9-18. 2010..Progress on preclinical and clinical evaluation of these novel targets in melanoma will be reviewed...- Investigation of the molecular profile of basal cell carcinoma using whole genome microarraysLorraine O'Driscoll
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
Mol Cancer 5:74. 2006.... - Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesAlex J Eustace
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
J Transl Med 6:53. 2008..Dasatinib, a multi-target kinase inhibitor, is currently approved for the treatment of chronic myeloid leukaemia and has shown promising results in preclinical studies in a number of solid tumours... - Alterations in integrin expression modulates invasion of pancreatic cancer cellsNaomi Walsh
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
J Exp Clin Cancer Res 28:140. 2009..Factors mediating the invasion of pancreatic cancer cells through the extracellular matrix (ECM) are not fully understood... - The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsSharon A Glynn
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
BMC Cancer 8:9. 2008..We examined the effects of statin drugs on in vitro proliferation, migration and invasion of melanoma cells... - EGFR and HER-2 antagonists in breast cancerNorma O'Donovan
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
Anticancer Res 27:1285-94. 2007..This may be due to difficulty in selecting the appropriate patient population, caused by the lack of definitive predictive markers for response to EGFR inhibition... - Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cellsNorma O'Donovan
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
Invest New Drugs 29:752-9. 2011..Dual targeting of EGFR and HER-2, by combining trastuzumab with EGFR/HER-2 tyrosine kinase inhibitors, may improve response in HER-2 overexpressing breast cancer cells that also express EGFR... - Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancerB Corkery
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin
Ann Oncol 20:862-7. 2009..Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC. We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines... - HER-2 signaling and inhibition in breast cancerB C Browne
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
Curr Cancer Drug Targets 9:419-38. 2009..Increased understanding of HER-2 signaling in breast cancer, and of response and resistance to HER-2 antagonists, will aid the development of strategies to overcome resistance to HER-2 targeted therapies... - Src: a potential target for the treatment of triple-negative breast cancerD Tryfonopoulos
Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
Ann Oncol 22:2234-40. 2011..The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer... - Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cellsB C Browne
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
Ann Oncol 22:68-73. 2011..We tested IGF1R inhibition to determine if dual targeting of HER-2 and IGF1R improves response in cell line models of acquired trastuzumab resistance... - Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell linesD M Collins
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
Invest New Drugs 28:433-44. 2010..Our observations suggest that the combination of lapatinib with a taxane or anthracycline warrants clinical investigation in NSCLC to examine if beneficial or detrimental interactions may result... - 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteinsPaul Dowling
The National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
Electrophoresis 28:4302-10. 2007..The identification of lung cancer-specific biomarkers is crucial to early detection, which in turn could lead to a dramatic increase in survival rates... - Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinomaNaomi Walsh
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
BMC Urol 9:6. 2009..The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease... - Synthesis, characterisation and biological evaluation of N-(ferrocenyl)naphthoyl amino acid esters as anticancer agentsAine Mooney
School of Chemical Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland
Dalton Trans 39:8228-39. 2010..N-(6-ferrocenyl-2-naphthoyl)-gamma-aminobutyric acid ethyl ester 17 shows a particularly high activity in both the H1299 cell line (IC(50) = 0.62 +/- 0.07 microM) and the Sk-Mel-28 cell line (IC(50) = 1.41 +/- 0.04 microM)... - Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissueVanesa Martinez
National Institute for Cellular Biotechnology NICB, Dublin City University, Dublin 9, Ireland
Breast Cancer Res Treat 110:521-30. 2008..0028). Multivariate analysis indicated GST A1 expression to be an independent prognostic factor for overall survival (P = 0.045). Our results suggest a possible use of ARNT2 and GST A1 as prognostic breast cancer biomarkers... - Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic studyAnnemarie Larkin
National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
Int J Cancer 112:286-94. 2004..No association was shown between MDR-1 Pgp expression and either RFS or OS time in any subgroup of patients... - Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?John Crown
St Vincent's University Hospital, 4, Dublin, Ireland
Lancet 362:677-8. 2003 - Chemotherapy for metastatic breast cancer-report of a European expert panelJohn Crown
Vincent's University Hospital, Dublin, Ireland
Lancet Oncol 3:719-27. 2002..Novel oral therapies have now been developed and are being used increasingly in patients whose disease has progressed following taxane therapy... - Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapyJohn Crown
St Vincent s University Hospital, Dublin, Ireland
Breast Cancer Res Treat 79:S11-8. 2003.... - Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experienceJohn Crown
Medical Oncology Research Unit, St Vincent s University Hospital, Dublin, Ireland
Oncologist 9:24-32. 2004.... - Prevalence and prognostic and predictive relevance of PRAME in breast cancerPadraig Doolan
National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
Breast Cancer Res Treat 109:359-65. 2008..Our results suggest that PRAME mRNA expression may be a useful prognostic and predictive marker for breast cancer... - High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancerMichael J Duffy
Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
Clin Chem 50:559-63. 2004..CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease... - Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-upRichard E Power
The Adelaide and Meath Hospital Incorporating the National Children's Hospital, Tallaght, Dublin, Ireland
Int J Urol 12:378-82. 2005..CONCLUSION: This significant incidence of pelvic recurrence questions the validity of modern radiotherapy protocol which excludes the ipsilateral pelvis from the radiation field... - A personalized approach to cancer treatment: how biomarkers can helpMichael J Duffy
Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
Clin Chem 54:1770-9. 2008..quot; This practice is inefficient and frequently results in inappropriate therapy and treatment-related toxicity. In contrast, personalized treatment has the potential to increase efficacy and decrease toxicity... - Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer
Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
N Engl J Med 355:2733-43. 2006..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients... - Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq
Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
Mol Cancer Ther 3:1207-14. 2004..b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial... - Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram
Oncology Research Network, David Geffen School of Medicine, and Division of Hematology/Oncology, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:759-69. 2004..The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings... - Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trialPrudence Francis
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
J Natl Cancer Inst 100:121-33. 2008..The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent administration of doxorubicin and docetaxel... - 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot studyAntonio Fabiano Ferreira Filho
Jules Bordet Institute, Brussels, Belgium
Anticancer Res 22:2471-6. 2002..CONCLUSION: The efficacy of these docetaxel-based regimens, in terms of OS and DFS, appears to be at least as good as standard anthracycline-based adjuvant chemotherapy (CT), in similar high-risk patient populations... - Caspase 3 in breast cancerNorma O'Donovan
Department of Medical Oncology, St Vincent s University Hospital, University College Dublin, Dublin 4, Ireland
Clin Cancer Res 9:738-42. 2003..One of the key mediators of apoptosis is the thiol protease caspase 3. In this investigation, caspase 3 mRNA and protein expression in breast cancer was examined... - Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxelJosephine Ballot
J Natl Cancer Inst 95:831-2. 2003 - Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trialRobert C F Leonard
South West Wales Cancer Institute, Singleton Hospital, Swansea, Wales, UK
J Natl Cancer Inst 96:1076-83. 2004..We compared the benefits of a single cycle of high-dose chemotherapy and the benefits of conventional chemotherapy in patients with high-risk breast cancer in a prospective, unblinded, randomized trial... - Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancerJohn Crown
St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
Lancet 364:1299-300. 2004 - Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group studyT R Jeffry Evans
Cancer Research United Kingdom Department of Medical Oncology, University of Glasgow, Beatson Laboratories, Garscube Estate, Switchback Rd, Glasgow G61 1BD, United Kingdom
J Clin Oncol 23:2988-95. 2005..CONCLUSION In contrast to the positive results reported for sequential docetaxel after AC as primary chemotherapy of breast cancer, our data do not suggest a benefit for simultaneous AD over AC... - Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancerMiguel Martin
JAMA 294:2166; author reply 2166-7. 2005 - High-dose chemotherapy for solid tumors: results of the EBMTGiovanni Rosti
EBMT Solid Tumors Working Party, Chairman Dr G Rosti, Ospedale Civile, Viale Randi 5, 48100, Ravenna, Italy
Crit Rev Oncol Hematol 41:129-40. 2002..This paper will describe the EBMT Solid Tumors Working Party Registry updated results as well as the main ongoing studies...